Logo.png
Gene and Cell Therapies Targeting CNS Disorders Market is Predicted to Exhibit Remarkable Growth by 2032, Predicts DelveInsight
February 14, 2024 13:00 ET | DelveInsight Business Research LLP
New York, USA, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Gene and Cell Therapies Targeting CNS Disorders Market is Predicted to Exhibit Remarkable Growth by 2032, Predicts DelveInsight   The gene and cell...
avenue.png
Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders
November 08, 2022 08:30 ET | Avenue Therapeutics
NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization...
logo.jpg
Vallon Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 03, 2022 16:30 ET | Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
logo.jpg
Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR
May 12, 2022 08:30 ET | Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, May 12, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
Logo.jpg
Endonovo Therapeutics Inc. (ENDV) Appoints Garry Michael Kann As Head of Corporate Development To Identify And Acquire Profitable Companies For Endonovo
March 01, 2022 09:10 ET | Endonovo Therapeutics, Inc.
Los Angeles, CA, March 01, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTC-ENDV), a developer and distributor of Innovative Medical Devices is pleased to announce that it has appointed...
logo.jpg
Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit
May 07, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
Live video webcast with David Baker, President and CEO of Vallon on Tuesday, May 18, 2021 at 4:15 PM ET PHILADELPHIA, PA, May 07, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ:...
logo.jpg
Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum
April 26, 2021 09:05 ET | Vallon Pharmaceuticals Inc.
David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel on April 29th at 10:30 AM ET PHILADELPHIA, PA, April 26, 2021 (GLOBE NEWSWIRE) -- Vallon...
logo.jpg
Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval
April 13, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021- Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines...
logo.jpg
Vallon Pharmaceuticals Announces Pricing of Initial Public Offering
February 09, 2021 22:24 ET | Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that...
logo.jpg
Vallon Pharmaceuticals Announces Presentation of ADAIR Pharmacokinetics and Pharmacodynamic Data at the Virtual 2021 APSARD Annual Meeting
January 19, 2021 08:30 ET | Vallon Pharmaceuticals Inc.
ADAIR demonstrated bioequivalence to immediate release (IR) d-AMPH when administered orally and appears to be less desirable to recreational drug abusers when snorted compared to currently available...